Fed’s Powell opens door to potential rate cuts at Jackson Hole
In a challenging year for 4D Molecular Therapeutics (FDMT), the biotech company’s stock has hit a 52-week low, trading at $3.68. With a market capitalization of $169.47 million, InvestingPro analysis suggests the stock is currently undervalued, while analyst price targets range from $6 to $65. This price level reflects a significant downturn from its previous performance, with the stock experiencing a precipitous 1-year change, plummeting by -89.11%. Investors have been closely monitoring FDMT as it navigates through a period marked by volatility and uncertainty within the biotech sector, with the company’s latest low serving as a stark indicator of the hurdles it faces. InvestingPro subscribers have access to 16 additional exclusive ProTips and a comprehensive Pro Research Report, offering deeper insights into FDMT’s financial health and market position.
In other recent news, 4D Molecular Therapeutics reported promising interim results from its Phase 2b PRISM clinical trial, showing a significant reduction in supplemental injections for wet age-related macular degeneration (wAMD) patients. The data revealed an 83% reduction in the need for additional aflibercept injections, with 57% of patients remaining injection-free over 52 weeks. Meanwhile, Jefferies adjusted its price target for the company to $40, citing the updated trial data, while maintaining a Buy rating. H.C. Wainwright also reaffirmed a Buy rating with a $36 price target, highlighting the positive trial outcomes and the potential impact on upcoming Phase 3 trials.
Conversely, BMO Capital Markets downgraded 4D Molecular Therapeutics to Market Perform, expressing concerns about the market reach and durability of 4D-150, especially for patients not newly diagnosed. The firm set a new price target of $15, noting the limited applicability of the drug to a smaller segment of the wAMD patient population. Leerink Partners lowered its price target to $27, maintaining an Outperform rating, following the company’s pipeline updates and strategic resource reallocation. These developments come as 4D Molecular Therapeutics plans to initiate two additional trials, 4FRONT-1 and 4FRONT-2, in 2025, aiming to further assess the efficacy and safety of its gene therapy candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.